Allakos Inc. (ALLK)
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
$51.20M
Dr. Robert Alexander Ph.D.
192.00
Redwood City, CA
Jul 19, 2018
-0.25
$-2.35
0.74
3.57
-1,915.20%
-0.24
0.00
0.59
4.63
3.57
-131.66%
-142.60%
Similar stocks (22)
Revolution Medicines, Inc.
RVMD
Blueprint Medicines Corporation
BPMC
Ultragenyx Pharmaceutical Inc.
RARE
Apellis Pharmaceuticals, Inc.
APLS
Crinetics Pharmaceuticals, Inc.
CRNX
Arvinas, Inc.
ARVN
Kura Oncology, Inc.
KURA
Arcus Biosciences, Inc.
RCUS
Day One Biopharmaceuticals, Inc.
DAWN
Sana Biotechnology, Inc.
SANA
Annexon, Inc.
ANNX
Allogene Therapeutics, Inc.
ALLO
Fate Therapeutics, Inc.
FATE
G1 Therapeutics, Inc.
GTHX
Heron Therapeutics, Inc.
HRTX
Sangamo Therapeutics, Inc.
SGMO
Caribou Biosciences, Inc.
CRBU
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
Atara Biotherapeutics, Inc.
ATRA
NextCure, Inc.
NXTC
ETF Exposure (15)
John Hancock Multifactor Small Cap ETF
JHSC
0.18%
iShares Micro-Cap ETF
IWC
0.01427%
Fidelity Nasdaq Composite Index ETF
ONEQ
0%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Quantitative Funds - Vanguard Growth and Income Fund
VGIAX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Growth and Income Fund
VQNPX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (22)
Revolution Medicines, Inc.
RVMD
Blueprint Medicines Corporation
BPMC
Ultragenyx Pharmaceutical Inc.
RARE
Apellis Pharmaceuticals, Inc.
APLS
Crinetics Pharmaceuticals, Inc.
CRNX
Arvinas, Inc.
ARVN
Kura Oncology, Inc.
KURA
Arcus Biosciences, Inc.
RCUS
Day One Biopharmaceuticals, Inc.
DAWN
Sana Biotechnology, Inc.
SANA
Annexon, Inc.
ANNX
Allogene Therapeutics, Inc.
ALLO
Fate Therapeutics, Inc.
FATE
G1 Therapeutics, Inc.
GTHX
Heron Therapeutics, Inc.
HRTX
Sangamo Therapeutics, Inc.
SGMO
Caribou Biosciences, Inc.
CRBU
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
Atara Biotherapeutics, Inc.
ATRA
NextCure, Inc.
NXTC
ETF Exposure (15)
John Hancock Multifactor Small Cap ETF
JHSC
0.18%
iShares Micro-Cap ETF
IWC
0.01427%
Fidelity Nasdaq Composite Index ETF
ONEQ
0%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Quantitative Funds - Vanguard Growth and Income Fund
VGIAX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Growth and Income Fund
VQNPX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%